Vanda Pharmaceuticals

Type: Company
Name: Vanda Pharmaceuticals
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

JOHN PAULSON : Paulson & Co. Opens Positions in Covidien, DirecTV and Allergan

By Maria ArmentalPaulson & Co. has taken new positions in Covidien PLC ( >> Covidien plc ) and DirecTV and sold off holdings in American Airlines Group Inc. ( >> American Airlines Group Inc ) , General Motors Co. ( >> General Motors ... [Published 4 Traders - Aug 14 2014]
First reported Aug 12 2014 - Updated Aug 13 2014 - 1 reports

Short Interest In Vanda Pharmaceuticals Expands By 15.2%

at 14:54 PM EDT The most recent short interest data has been released by the NASDAQ for the 07/31/2014 settlement date, which shows a 1,034,324 share increase in total short interest for Vanda Pharmaceuticals Inc (VNDA), to 7,835,316, an increase of 15.21% ... [Published Fat Pitch Financials - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 1 reports

Volume Spike Detected in Shares of Vanda Pharmaceuticals as They Move Higher on 1.5x Above-Average Volume (VNDA)

(Financial News Network On) Vanda Pharmaceuticals shares are trading on heavy volume today, having risen 6.0% to $12.78. Today's volume of 792,000 shares tops the average 30-day volume of 542,000 shares. Spikes in volume can validate a breakout or signify ... [Published Individual.com - Aug 11 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Buyers Accumulate Shares of Vanda Pharmaceuticals, Up 7.0%

Written on Mon, 08/11/2014 - 12:29pmBy Nick RussoVanda Pharmaceuticals ( NASDAQ:VNDA ) is one of today's notable stocks on the rise, up 7.0% to $12.91. The Dow is up 0.4% to 16,613 and the S&P is currently up 0.6% to 1,943.Vanda Pharmaceuticals is in ... [Published Comtex SmarTrend - Aug 11 2014]
First reported Aug 07 2014 - Updated Aug 08 2014 - 1 reports

Notable Two Hundred Day Moving Average Cross - VNDA

In trading on Thursday, shares of Vanda Pharmaceuticals Inc (VNDA) crossed below their 200 day moving average of $12.90, changing hands as low as $12.70 per share. Vanda Pharmaceuticals Inc shares are currently trading down about 5.7% on the day.. ... [Published Town Hall - Aug 07 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Vanda Pharmaceuticals Sees Strong Trading Volume After Strong Earnings (VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA) shares saw unusually-high trading volume on Thursday following a stronger than expected earnings report, reports. Approximately 1,372,568 shares were traded during trading, an increase of 125% from the previous session’s ... [Published American Banking News - Aug 07 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 2 reports

Vanda Pharmaceuticals Reports Second Quarter 2014 Results

"We are encouraged by the early positive reception of HETLIOZ by patients, physicians and payors. We look forward to more patients benefiting from HETLIOZ in the coming months and years," said Mihael PolymeropoulosKey Highlights:SECOND QUARTER 2014 REPORTED ... [Published Digital Producer - Aug 07 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 2 reports

Vanda Pharmaceuticals Reports Second Quarter 2014 Results

WASHINGTON, Aug. 7, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced ... [Published Bio-Medicine - Aug 07 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Vanda updates expense guidance after Q2 results

07:54 ET | About: Vanda Pharmaceuticals Inc. (VNDA)Vanda Pharmaceuticals (VNDA -2.8%) Q2 results: Total Revenues: $10.9M (+31.3%); Operating Expenses: $32.5M (+177.8%); Operating Loss: ($21.6M) (-535.3%); Net Loss: ($21.6M) (-535.3%); Loss Per Share: ... [Published Seeking Alpha - Aug 07 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Vanda Pharmaceuticals beats by $0.06, beats on revenue

07:05 ET | About: Vanda Pharmaceuticals Inc. (VNDA)Vanda Pharmaceuticals (NASDAQ:VNDA): Q2 EPS of -$0.64 beats by $0.06.Revenue of $10.9M (+31.0% Y/Y) beats by $ ... [Published Seeking Alpha - Aug 07 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

VANDA PHARMACEUTICALS : Patent Issued for Treatment of Circadian Rhythm Disorders

By a News Reporter-Staff News Editor at Biotech Week -- From Alexandria, Virginia , NewsRx journalists report that a patent by the inventors Dressman, Marlene Michelle ( Germantown, MD ); Feeney, John Joseph ( Olney, MD ); Licamele, Louis William ( Potomac, ... [Published 4 Traders - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Highest EPS Growth in the Biotechnology Industry Detected in Shares of Vanda Pharmaceuticals (VNDA, GILD, SGEN, ALKS, REGN)

(Comtex SmarTrend(R)) Below are the three companies in the Biotechnology industry with the highest year-over-year expected earnings per share (EPS) growth rates. Vanda Pharmaceuticals ranks highest with a EPS growth of 536.4%. Gilead Sciences is next ... [Published Individual.com - Jul 30 2014]

Quotes

...To learn more about that story, check-out " The Greatest Trade Ever: The Behind-the-Scenes Story of How John Paulson Defied Wall Street and Made Financial History "
"We are encouraged by the early positive reception of HETLIOZ by patients, physicians and payors. We look forward to more patients benefiting from HETLIOZ in the coming months and years" said Mihael Polymeropoulos MD, President and CEO of Vanda Pharmaceuticals
"Non-24, also referred to as Non-24-Hour Sleep-Wake Disorder (N24HSWD) or Non-24-Hour Disorder, is an orphan indication affecting approximately 65,000 to 95,000 people in the U S and 140,000 in Europe . Non-24 occurs when individuals, primarily blind with no light perception, are unable to synchronize their endogenous circadian pacemaker to the 24-hour light/dark cycle. Without light as a synchronizer, and because the period of the internal clock is typically a little longer than 24 hours, individuals with Non-24 experience their circadian drive to initiate sleep drifting later and later each day. Individuals with Non-24 have abnormal night sleep patterns, accompanied by difficulty staying awake during the day. Non-24 leads to significant impairment, with chronic effects impacting the social and occupational functioning of these individuals."

More Content

All (53) | News (25) | Reports (0) | Blogs (22) | Audio/Video (0) | Fact Sheets (0) | Press Releases (6)
sort by: Date | Relevance
The Wildest Biotech Stock Out There [Published Benzinga.com - Aug 19 2014]
Tracking John Paulson's Paulson & Company Portf... [Published Seeking Alpha - Aug 18 2014]
Hedge Funds Disclose Positions: What They've Be... [Published Forbes.com - Aug 15 2014]
JOHN PAULSON : Paulson & Co. Opens Positions in... [Published 4 Traders - Aug 14 2014]
Expert Briefing on Biotech Stocks -- Nanosphere... [Published Financial Services - Aug 14 2014]
Short Interest In Vanda Pharmaceuticals Expands... [Published Fat Pitch Financials - Aug 12 2014]
Leading Small-Cap Stars Health Care Stock for A... [Published Equities.com - Aug 11 2014]
Volume Spike Detected in Shares of Vanda Pharma... [Published Individual.com - Aug 11 2014]
Buyers Accumulate Shares of Vanda Pharmaceutica... [Published Comtex SmarTrend - Aug 11 2014]
Vanda Pharmaceuticals Sees Strong Trading Volum... [Published American Banking News - Aug 07 2014]
Notable Two Hundred Day Moving Average Cross - ... [Published Town Hall - Aug 07 2014]
Vanda Pharmaceuticals Reports Second Quarter 20... [Published Bio-Medicine - Aug 07 2014]
Vanda Pharmaceuticals Reports Second Quarter 20... [Published Digital Producer - Aug 07 2014]
Vanda updates expense guidance after Q2 results [Published Seeking Alpha - Aug 07 2014]
Vanda Pharmaceuticals beats by $0.06, beats on ... [Published Seeking Alpha - Aug 07 2014]
Vanda Pharmaceuticals Reports Second Quarter 20... [Published Fox Toledo - Aug 07 2014]
Vanda Pharmaceuticals Reports Second Quarter 20... [Published PR Newswire: Financial Services - Aug 07 2014]
VANDA PHARMACEUTICALS : Patent Issued for Treat... [Published 4 Traders - Jul 31 2014]
Highest EPS Growth in the Biotechnology Industr... [Published Individual.com - Jul 30 2014]
Vanda Pharmaceuticals to Announce Second Quarte... [Published PR Newswire: Health - Jul 18 2014]
New Patents, Clinical Trial Updates, New Agreem... [Published Financial Services - Jun 26 2014]
Morning Analysis on Top Gainers -- Research on ... [Published Financial Services - Jun 05 2014]
Stocks: New High for the S&P 500; Under Armour ... [Published BARRONS.com Stocks To Watch Today - Jun 04 2014]
Why Vanda Pharmaceuticals (VNDA) Stock Is Surgi... [Published The Street Latest - Jun 04 2014]
EMA accepts Vanda's marketing application for N... [Published PBR - News - Jun 04 2014]
European Medicines Agency Accepts HETLIOZ™ (tas... [Published PR Newswire: Health - Jun 03 2014]
HETLIOZ™ (tasimelteon) Data in Patients with No... [Published PR Newswire: General Business - Jun 03 2014]
Vanda Pharmaceuticals to Present at the Jefferi... [Published PR Newswire: General Business - May 30 2014]
Clinical Trial Updates, Leadership Appointments... [Published PR Newswire: Financial Services - May 15 2014]
Forget Rent: The Cost of These 5 New Drugs Is T... [Published Wall St. Cheat Sheet - May 13 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Vanda Pharmaceuticals Reports Second Quarter 20... [Published PR Newswire: Financial Services - Aug 07 2014]
WASHINGTON, Aug. 7, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced ...
Vanda Pharmaceuticals to Announce Second Quarte... [Published PR Newswire: Health - Jul 18 2014]
WASHINGTON, July 17, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced ...
Stocks: New High for the S&P 500; Under Armour ... [Published BARRONS.com Stocks To Watch Today - Jun 04 2014]
It was the night before the ECB–and two before US payrolls–and all through the market nothing was stirring, not even…Alright. Some things were stirring, like the shares of Protective Life (PL), Travelers Companies (TRV), Under Armour (UA), Broadcom (BRCM) ...
EMA accepts Vanda's marketing application for N... [Published PBR - News - Jun 04 2014]
The European Medicines Agency (EMA) has accepted to evaluate Vanda Pharmaceuticals' Marketing Authorization Application (MAA) for oral HETLIOZ (tasimelteon) capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). ...
European Medicines Agency Accepts HETLIOZ™ (tas... [Published PR Newswire: Health - Jun 03 2014]
WASHINGTON, June 3, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines ...
1 2 3 4 5

Press Releases

sort by: Date | Relevance
Expert Briefing on Biotech Stocks -- Nanosphere... [Published Financial Services - Aug 14 2014]
New Patents, Clinical Trial Updates, New Agreem... [Published Financial Services - Jun 26 2014]
Morning Analysis on Top Gainers -- Research on ... [Published Financial Services - Jun 05 2014]
Biotech Stocks on our Radar -- Research on Immu... [Published Financial Services - May 09 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published Financial Services - Apr 10 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.